Nitroindoline-caged GABA (Cat.No. 0344) with similar photochemical properties to MNI-glutamate (Cat. No. 1490); for example, the same quantum yield (0.085). Highly water soluble; exhibits fast photorelease that is efficient at near-UV and 405 nm wavelengths.
Sold under licence from the Medical Research Council.
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
|water||1||2mM with gentle warming|
Preparing Stock Solutions
The following data is based on the product molecular weight 499.3. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2 mL||10.01 mL||20.03 mL|
|5 mM||0.4 mL||2 mL||4.01 mL|
|10 mM||0.2 mL||1 mL||2 mL|
|50 mM||0.04 mL||0.2 mL||0.4 mL|
References are publications that support the products' biological activity.
Wieboldt et al (1994) Synthesis and photochemistry of photolabile derivatives of gamma-aminobutyric acid for chemical kinetic investigations of the gamma-aminobutyric acid receptor in the millisecond time region. Biochemistry 33 1526 PMID: 8312272
Trigo et al (2009) Laser photolysis of DPNI-GABA, a tool for investigating the properties and distribution of GABA receptors and for silencing neurons in situ. J.Neurosci.Meths. 181 159 PMID: 19422852
Trigo (2010) Presynaptic miniature GABAergic currents in developing interneurons. Neuron 66 235 PMID: 20435000
If you know of a relevant reference for DPNI-caged-GABA, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: DPNI-caged-GABA, supplier, nitroindoline, reduces, peak, GABA-evoked, responses, caged, compounds, Caged, GABA, Compounds, GABAA, Receptors, GABAA, Receptors, Tocris Bioscience
1 Citation for DPNI-caged-GABA
Citations are publications that use Tocris products. Selected citations for DPNI-caged-GABA include:
Nunez-Parra et al (2013) Disruption of centrifugal inhibition to olfactory bulb granule cells impairs olfactory discrimination. PLoS One 110 14777 PMID: 23959889
Do you know of a great paper that uses DPNI-caged-GABA from Tocris? If so please let us know.
Reviews for DPNI-caged-GABA
There are currently no reviews for this product. Be the first to review DPNI-caged-GABA and earn rewards!
Have you used DPNI-caged-GABA?
Submit a review and receive an Amazon gift card.
$10US/$10CAN/€7/£6 gift card for a review without an image
$25US/$25CAN/€18/£15 gift card for a review with an image
*Offer only valid in the USA / Canada, UK and EuropeSubmit a Review
Literature in this Area
GABA Receptors Scientific Review
Written by Ian Martin, Norman Bowery and Susan Dunn, this review provides a history of the GABA receptor, as well as discussing the structure and function of the various subtypes and the clinical potential of receptor modulators; compounds available from Tocris are listed.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.